Operating Income - Daewoong Pharma (KRX:069620) - Alpha Spread

Daewoong Pharma
KRX:069620

Watchlist Manager
Daewoong Pharma Logo
Daewoong Pharma
KRX:069620
Watchlist
Price: 138 700 KRW -0.93% Market Closed
Market Cap: 1.6T KRW
Have any thoughts about
Daewoong Pharma?
Write Note

Daewoong Pharma
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Daewoong Pharma
Operating Income Peer Comparison

Comparables:
000100
326030
128940
S
000250
C
068760

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Daewoong Pharma
KRX:069620
Operating Income
â‚©130B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
7%
Yuhan Corp
KRX:000100
Operating Income
â‚©26B
CAGR 3-Years
-36%
CAGR 5-Years
25%
CAGR 10-Years
-9%
SK Biopharmaceuticals Co Ltd
KRX:326030
Operating Income
-â‚©37.5B
CAGR 3-Years
46%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Operating Income
â‚©262.4B
CAGR 3-Years
68%
CAGR 5-Years
25%
CAGR 10-Years
16%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Operating Income
â‚©7.4B
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-9%
C
Celltrion Pharm Inc
KOSDAQ:068760
Operating Income
â‚©22.2B
CAGR 3-Years
-18%
CAGR 5-Years
42%
CAGR 10-Years
13%

See Also

What is Daewoong Pharma's Operating Income?
Operating Income
130B KRW

Based on the financial report for Jun 30, 2024, Daewoong Pharma's Operating Income amounts to 130B KRW.

What is Daewoong Pharma's Operating Income growth rate?
Operating Income CAGR 10Y
7%

Over the last year, the Operating Income growth was 21%. The average annual Operating Income growth rates for Daewoong Pharma have been 33% over the past three years , 32% over the past five years , and 7% over the past ten years .

Back to Top